FDA Clears Siren's First IND For SRN-101, Enabling Their PhI/II Trail

READ MORE  ►

Engage Bio Has Been Awarded a Grant From the Gates Foundation to Extend the Reach of Their Non-Viral DNA Medicine Platform Into Global Health.

READ MORE  ►

XPose Therapeutics Acquired By Mid-Atlantic BioTherapeutics, Expanding Its Pipeline and Leadership Team

READ MORE  ►

Loyal Raises $100M Series C, Led by age1, to Advance the First Canine Longevity Drug

READ MORE  ►

Sift Biosciences Announces Oversubscribed $3.7M Pre-seed Financing to Advance Next-generation T-cell Immunotherapy Platform

READ MORE  ►

MBC BioLabs Announces New Partnership With Paul Hastings LLP

READ MORE  ►

Founders at Work: Dispatch Bio

March 3 @ noon - 1pm
135 Mississippi St, San Francisco

Dispatch Bio was founded with a bold purpose: to help create a world where all cancer patients can be cured. To achieve this, they're engineering a universal treatment across solid tumors, leveraging their first-in-class Flare platform.

Join us for lunch and hear from Sabah Oney, Ph.D., Chief Executive Officer, Lex Johnson, Ph.D., Co-Founder and Chief Platform Officer, and Ray Liu, Ph.D., Co-Founder and Head of Synthetic Biology of Dispatch Bio. Hear how they've brought together leaders in cellular engineering, synthetic biology, protein design, and tumor microenvironment biology to confront the fundamental barriers limiting immunotherapy treatments in solid tumors.

REGISTER ►

Life Science Schowcase

March 11 @ 11am - 2pm
1030 Brittan Ave, San Carlos

MBC BioLabs is kicking off 2026 with our first Life Sciences Showcase - and we’d love to have you there! Join us to meet a curated mix of life science equipment and service providers, explore the space, and connect with our resident community. Whether you’re optimizing a workflow, scouting your next capability, or just curious about what’s new, this is a great chance to get hands-on with the tools powering today’s research - and swap notes with the people who build and use them.

At the Showcase, you’ll be able to:
🔬 See what’s new in research tools, platforms, and enabling technologies
🤝 Talk shop with experts - ask questions, troubleshoot, and compare options
💡 Spark collaborations with fellow scientists and biotech builders
🌮 Enjoy a complimentary lunch on us

Come for the science, stay for the connections (and tacos).

Registration is free — save your spot today!

REGISTER ►

MBC BioLabs Longevity Innovation Forum

April 2 @ 3 - 7:30pm
1030 Brittan Ave, San Carlos

Join us for our fifth Innovation Forum, where we'll highlight pioneering startups reimagining how we prevent and treat age-related disease. We’re bringing together the community of founders, funders, and partners driving the future of healthspan. Space is limited and priority registration will be granted to founders and funders building in longevity.

REGISTER ►

PinPrint is revolutionizing the patient experience for both drug delivery and tissue sampling with our unique, high resolution, 3D printed microarray products. Our approach enables device designs that cannot be produced with traditional molding methods. We are developing microneedle array patch (“MAP”) technologies that can be used to deliver dry and stabilized product, or as microfluidic-backed MAPs that can be attached to a syringe or ampule pre-filled with drug product for direct intradermal liquid injection. Founded in 2023, we officially started operations in early 2025, and have raised $5M of which $1.6M is from two non-dilutive research and development collaborations.

We’re excited to welcome them to our community at 1030 Brittan.

SonALAsense Inc is a pioneer of Sonodynamic Therapy (SDT), a drug-device combination that is a non-invasive approach to treat cancer without significant side effects. The drug is SONALA-001, an intravenous formulation of 5-aminolevulinic acid, and the device delivers low intensity ultrasound. The first clinical trial of SONALA-001 SDT in recurrent high-grade gliomas (Sanai et al., Science Translational Medicine, 2025, 17: 826) demonstrated that SDT operates by the same mechanism as photodynamic therapy, where ultrasound creates light in tissue to create a ‘Reactive Oxygen Species implosion’ to kill brain cancer cells without affecting normal brain tissue. In a subsequent clinical trial, SonALAsense generated compelling initial clinical proof-of-concept data in a pediatric brain cancer called Diffuse Intrinsic Pontine Glioma, where SDT caused tumor regression, gain of function, and an extension of survival. In December 2024, SonALAsense received a $46.6MM ARPA-H award to fund the development of SDT in blood cancers.

A warm welcome for joining us at 1030 Brittan!

Taudia is a precision proteomics company advancing blood-based biomarker detection through an ultrasensitive protein quantification platform. Enabled by a proprietary single-wash proximity ligation chemistry, the technology achieves fg/mL-level sensitivity using standard qPCR and dPCR instruments. With a streamlined workflow requiring only 10 µL of sample, Taudia is initially focused on neurodegenerative diseases, supporting biomarker discovery, translational research, and longitudinal monitoring.

Join us in welcoming them to 1030 Brittan!

Ridge Biotechnologies is pioneering AI-based enzyme and targeted drug design to power the next wave of precision therapeutics. Backed by Sutter Hill Ventures and led by a collection of established biotech entrepreneurs and faculty from top institutions including Stanford and MIT, Ridge Bio uses proprietary machine learning models informed by high-throughput cell-free experimentation for a wide range of applications in antibody-drug conjugates (ADCs), conditionally active prodrugs, targeted nucleic acid delivery, radiotherapies, and enzyme-based therapeutics. Their current product lines include NativeLink enzymes that build bioconjugates like ADCs with superior stability and efficacy, ProTrigger linkers that provide tissue and disease-specific activation and release of diverse payloads and prodrugs, and new classes of enzyme-based Catalytic Medicines. Ridge Bio is focused on enabling our partners to build better drugs for patients.

We’re delighted to welcome them at 1030 Brittan.

Serna Bio is an AI-enabled drug discovery company developing the next generation of small molecules to target RNA. Our lead focus is translational enhancers — a new class of therapeutics designed to address diseases driven by protein insufficiency.  At the core is the Serna Bio Discovery Platform, a tech stack for RNA drug discovery. It leverages proprietary data and unique computational pipelines. Our Biology platform is the world’s largest dataset of experimentally determined, functional RNA structures, enabling the identification of druggable RNA motifs within seconds. Complementing this is our ChemAI platform, which is a generative chemistry system trained on proprietary data. This platform designs selective small molecules to modulate RNA function, surpassing leading methodologies like NVIDIA MolMIMM for RNA-small molecule interactions.  This platform has enabled the creation of an entirely new therapeutic modality. We have established partnerships with leading pharmaceutical companies including Bayer and Chiesi, and are backed by top-tier investors including Y Combinator, Hummingbird Ventures, and Tencent.

Welcome to 1030 Brittan - we’re glad to have you here!